JP2011529503A5 - - Google Patents

Download PDF

Info

Publication number
JP2011529503A5
JP2011529503A5 JP2011521235A JP2011521235A JP2011529503A5 JP 2011529503 A5 JP2011529503 A5 JP 2011529503A5 JP 2011521235 A JP2011521235 A JP 2011521235A JP 2011521235 A JP2011521235 A JP 2011521235A JP 2011529503 A5 JP2011529503 A5 JP 2011529503A5
Authority
JP
Japan
Prior art keywords
acid
compound
alcohol
cis
double bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011521235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529503A (ja
JP5653917B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/051927 external-priority patent/WO2010014585A1/en
Publication of JP2011529503A publication Critical patent/JP2011529503A/ja
Publication of JP2011529503A5 publication Critical patent/JP2011529503A5/ja
Application granted granted Critical
Publication of JP5653917B2 publication Critical patent/JP5653917B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011521235A 2008-07-28 2009-07-28 神経変性疾患の治療のためのｐｋｃ活性化化合物 Expired - Fee Related JP5653917B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8417208P 2008-07-28 2008-07-28
US61/084,172 2008-07-28
PCT/US2009/051927 WO2010014585A1 (en) 2008-07-28 2009-07-28 Pkc-activating compounds for the treatment of neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014182597A Division JP2015042643A (ja) 2008-07-28 2014-09-08 神経変性疾患の治療のためのｐｋｃ活性化化合物

Publications (3)

Publication Number Publication Date
JP2011529503A JP2011529503A (ja) 2011-12-08
JP2011529503A5 true JP2011529503A5 (https=) 2012-09-13
JP5653917B2 JP5653917B2 (ja) 2015-01-14

Family

ID=41136734

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011521235A Expired - Fee Related JP5653917B2 (ja) 2008-07-28 2009-07-28 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP2014182597A Pending JP2015042643A (ja) 2008-07-28 2014-09-08 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP2016051212A Expired - Fee Related JP6449186B2 (ja) 2008-07-28 2016-03-15 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP2018111869A Pending JP2018168170A (ja) 2008-07-28 2018-06-12 神経変性疾患の治療のためのｐｋｃ活性化化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014182597A Pending JP2015042643A (ja) 2008-07-28 2014-09-08 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP2016051212A Expired - Fee Related JP6449186B2 (ja) 2008-07-28 2016-03-15 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP2018111869A Pending JP2018168170A (ja) 2008-07-28 2018-06-12 神経変性疾患の治療のためのｐｋｃ活性化化合物

Country Status (6)

Country Link
US (7) US8163800B2 (https=)
EP (3) EP3586839A1 (https=)
JP (4) JP5653917B2 (https=)
CA (2) CA2731171C (https=)
ES (1) ES2683021T3 (https=)
WO (1) WO2010014585A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090030055A1 (en) * 2002-07-02 2009-01-29 Thomas Nelson PKC activation as a means for enhancing sAPPALPHA secretion and improving cognition using bryostatin type compounds
CA2731171C (en) 2008-07-28 2016-10-18 Blanchette Rockefeller Neurosciences Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
US10052299B2 (en) 2009-10-30 2018-08-21 Retrotope, Inc. Alleviating oxidative stress disorders with PUFA derivatives
US20140038186A1 (en) * 2010-02-22 2014-02-06 Tapan Kumar Khan Alzheimer's disease-specific alterations of protein kinase c epsilon (pkc-epsilon) protein levels
US20120027687A1 (en) 2010-07-08 2012-02-02 Alkon Daniel L Fatty acid protein kinase c activators and anticoagulant for the treatment of stroke
EP2605773A1 (en) 2010-08-19 2013-06-26 Blanchette Rockefeller Neurosciences, Institute Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
WO2012148930A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Oxidative retinal diseases
JP6106157B2 (ja) 2011-04-26 2017-03-29 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． 神経変性障害および筋疾患に関与するｐｕｆａ
JP6145087B2 (ja) * 2011-04-26 2017-06-07 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ酸化関与障害
KR102112087B1 (ko) 2011-04-26 2020-05-18 레트로토프 인코포레이티드 에너지 프로세싱 손상 장애 및 미토콘드리아 결함
EP2764120B1 (en) 2011-10-05 2020-06-10 Blanchette Rockefeller Neurosciences, Institute Stimulus-elicited genomic profile markers of a neurodegenerative condition
CA2855932A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Pkc activators and combinations thereof
EP2780316B1 (en) * 2011-11-13 2020-04-15 Blanchette Rockefeller Neurosciences Institute Esters of dcpla and methods of treatment using the same
EP2957285B1 (en) * 2013-02-15 2018-01-10 Nishizaki Bioinformation Research Institute Phospholipid compound containing unsaturated fatty acid derivative having cyclopropane ring
JP2016516201A (ja) * 2013-03-15 2016-06-02 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 神経保護性ｐｋｃ活性化因子を特定する方法
US9962357B2 (en) 2013-10-18 2018-05-08 West Virginia University Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases
MX2016013680A (es) 2014-04-18 2017-07-05 Neurotrope Bioscience Inc Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos.
US9413754B2 (en) 2014-12-23 2016-08-09 Airwatch Llc Authenticator device facilitating file security
US20180217163A1 (en) 2015-05-11 2018-08-02 Daniel L. Alkon Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
WO2017053659A1 (en) 2015-09-23 2017-03-30 Khan Tapan K Methods for survival and rejuvenation of dermal fibroblasts using pkc activators
US20180311209A1 (en) 2015-10-08 2018-11-01 Cognitive Research Enterprises, Inc. Dosing regimens of pkc activators
EP3950649A1 (en) 2015-11-23 2022-02-09 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
JP6912072B2 (ja) * 2016-12-14 2021-07-28 国立大学法人山口大学 前頭側頭型認知症の予防又は治療用医薬
WO2018187647A1 (en) 2017-04-06 2018-10-11 Neurotrope Bioscience, Inc. Methods and compositions for treatment of neurological diseases, disorders, or conditions
EP3793543A1 (en) * 2018-05-18 2021-03-24 Neurotrope Bioscience, Inc. Methods and compositions for treatment of alzheimer's disease
WO2020118282A1 (en) * 2018-12-07 2020-06-11 The Johns Hopkins University Methods, compositions and kits for treating multiple sclerosis and other disorders
IL295783B2 (en) 2020-02-21 2026-03-01 Retrotope Inc Processes for isotopic alteration of polyunsaturated fatty acids and their derivatives
US20220133687A1 (en) * 2020-11-02 2022-05-05 Synaptogenix, Inc. Methods of treating and preventing neurodegenerative diseases with hgf activating compounds
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
WO2022170232A1 (en) * 2021-02-08 2022-08-11 Synaptogenix, Inc. Treatment of multiple sclerosis using pkc activators
WO2022170226A1 (en) * 2021-02-08 2022-08-11 Synaptogenix, Inc. Treatment of optic nerve inflammation using pkc activators
US20250345400A1 (en) * 2022-05-18 2025-11-13 Virginia Commonwealth University Methods for treatment of cognitive impairment in cirrhosis patients
WO2025056602A1 (en) 2023-09-11 2025-03-20 Elastin Biosciences Ltd. Pharmaceutical compositions and use thereof in treatment of conditions and diseases related to elastin deficiency and/or aging

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080784A (en) 1986-06-11 2000-06-27 Procyon Pharmaceuticals, Inc. Protein kinase C modulators N
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5242932A (en) 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
DK0618968T3 (da) 1991-12-06 2000-04-10 Max Planck Gesellschaft Midler til diagnostisering og behandling af Alzheimer's sygdom
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
JPH06279311A (ja) 1993-03-26 1994-10-04 Sagami Chem Res Center プロテインキナーゼｃアイソザイムの活性化剤
US6107050A (en) 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US5976816A (en) 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US20030108956A1 (en) 1993-05-03 2003-06-12 Alkon Daniel L. Cell tests for Alzheimer's disease
US7625697B2 (en) 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5863902A (en) 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6001580A (en) 1995-03-28 1999-12-14 Takeda Chemical Industries, Inc. Method for assaying ERK2 map kinase
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
AU2316797A (en) 1996-02-29 1997-09-16 Mount Sinai Hospital Corporation Shc proteins
JPH1090263A (ja) 1996-07-25 1998-04-10 Mclean Hospital Corp:The アルツハイマー病の診断のためのｅｒｋ−１およびｅｒｋ−２の利用
WO2000020867A1 (en) 1998-10-01 2000-04-13 Alexey Vladimirovich Titievsky A novel ret-independent signaling pathway for gdnf
WO2000070099A2 (en) 1999-05-19 2000-11-23 Mitokor Differential gene expression in specific regions of the brain in neurodegenerative diseases
WO2001027624A2 (en) 1999-10-08 2001-04-19 Superarray, Inc. Compositions and methods for detecting protein modification and enzymatic activity
US20030165481A1 (en) 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US6869772B2 (en) 2000-03-10 2005-03-22 Washington University Method for labeling individual cells
DE60124080T2 (de) 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
EP1268434A1 (en) 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of a-beta protein production
WO2001077086A1 (en) 2000-04-11 2001-10-18 Dupont Pharmaceuticals Company SUBSTITUTED LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION
JP2004502664A (ja) 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病処置用化合物
WO2002010768A2 (en) 2000-07-31 2002-02-07 The Regents Of The University Of California Model for alzheimer's disease and other neurodegenerative diseases
JP2004517892A (ja) 2000-12-13 2004-06-17 ワイス β−アミロイド産生の複素環スルホンアミド阻害剤
AUPR215700A0 (en) * 2000-12-19 2001-01-25 Fujisawa Pharmaceutical Co., Ltd. Carboxylic acid compound having cyclopropane ring
JP2004517619A (ja) 2000-12-21 2004-06-17 ノバルティス アクチエンゲゼルシャフト インターロイキン−１関連遺伝子およびタンパク質
WO2002063005A2 (en) 2001-02-06 2002-08-15 Incyte Genomics, Inc. Lipid-associated molecules
AU2002254029A1 (en) 2001-02-27 2002-09-12 Daniel L. Alkon Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
JP4024554B2 (ja) 2001-02-27 2007-12-19 松下電器産業株式会社 燃料電池発電システム
US6874208B2 (en) 2001-03-14 2005-04-05 Autoliv Asp, Inc. Anchoring attachment apparatus
BR0210721A (pt) 2001-06-27 2004-07-20 Elan Pharm Inc Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
US20040014678A1 (en) 2001-08-08 2004-01-22 Antonella Favit Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytoc pathway
WO2004083241A2 (en) 2003-03-19 2004-09-30 Takeda Pharmaceutical Company Limited Btc-interacting proteins and use thereof
US7595159B2 (en) 2004-11-03 2009-09-29 The Brigham And Women's Hospital, Inc. Prediction of Parkinson's disease using gene expression levels of peripheral blood samples
CA2582270A1 (en) 2004-11-15 2006-05-26 Blanchette Rockefeller Neurosciences Institute Abnormalities of phosphatase 2a (pp2a) for diagnosis and treatment of alzheimer's disease
WO2007019080A2 (en) 2005-08-03 2007-02-15 Merck & Co., Inc. Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007044094A1 (en) 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
EP1934618B1 (en) 2005-10-11 2009-05-13 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
WO2007043998A1 (en) 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio
US7595167B2 (en) 2005-10-11 2009-09-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
CN101478912A (zh) 2006-06-21 2009-07-08 莱克西克医疗技术有限公司 评估痴呆与痴呆型紊乱
JP2008143819A (ja) * 2006-12-08 2008-06-26 Tomoyuki Nishizaki 酸化ストレス誘導細胞死の抑制剤
EP3332797A3 (en) 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury
US20100209914A1 (en) 2007-05-25 2010-08-19 Ore Pharmaceuticals , Inc. Methods, systems, and kits for evaluating multiple sclerosis
EP2767541A1 (en) * 2008-03-03 2014-08-20 Rxbio, Inc. LPA receptor agonists and antagonists
CA2731171C (en) 2008-07-28 2016-10-18 Blanchette Rockefeller Neurosciences Institute Pkc-activating compounds for the treatment of neurodegenerative diseases

Similar Documents

Publication Publication Date Title
JP2011529503A5 (https=)
JP2018168170A5 (https=)
Kumar et al. Exploring the molecular approach of COX and LOX in Alzheimer’s and Parkinson’s disorder
JP2014512351A5 (https=)
JP2020500193A5 (https=)
Auvin Fatty acid oxidation and epilepsy
JP2010196060A5 (https=)
JP6953504B2 (ja) エイコサペンタエン酸アルキルエステルを含有する組成物及びその製造方法
JP2010519311A5 (https=)
JP2016538254A5 (https=)
JP2015143248A5 (https=)
Kawashima et al. Effects of eicosapentaenoic acid on synaptic plasticity, fatty acid profile and phosphoinositide 3-kinase signaling in rat hippocampus and differentiated PC12 cells
JP2012516852A5 (https=)
JP2016501248A5 (https=)
JP2017526623A5 (https=)
RU2019110681A (ru) Фармацевтическая композиция
JP2013538817A5 (https=)
UA111967C2 (uk) Оздоровчий харчовий продукт, що містить етилові естери жирних кислот з лляної олії, і спосіб його одержання
JP7242769B2 (ja) 遊離多価不飽和脂肪酸含有組成物及びその製造方法
JP2016501249A5 (https=)
Clarke et al. Chain reactions: early-life stress alters the metabolic profile of plasma polyunsaturated fatty acids in adulthood
JP2020182497A5 (https=)
JP2012513380A5 (https=)
JP2016523826A5 (https=)
Das Telomere length and polyunsaturated fatty acids